Search results
New report shows common medication puts at-risk individuals in danger — and heat is only making...
The Cool Down via Yahoo News· 7 days agoAs if you didn't have enough to do this time of year, add "check your medication regimen" to the ...
UK heatwave warning as common medication increases risk of overheating
Daily Express· 5 days agoWith temperatures finally hotting up in the UK many Brits are gearing up to enjoy the sun and the...
Three signs of high cholesterol that can be spotted on the body without a test
Daily Express· 5 days agoBrits are being urged to look out for three potential warning signs of a silent killer condition...
Gateway - Quartz
Quartz· 4 days agoNovo Nordisk’s nearly $1,000 per month diabetes medication Ozempic can be produced for less than $5 a month, according to a new study. Researchers at Yale ...
Gateway - Quartz
Quartz· 5 days agoNovo Nordisk is facing two-pronged pressure from lawmakers and patient advocates to make its popular diabetes medication Ozempic more affordable. Researchers ...
Gateway - Quartz
Quartz· 5 days agoMedicines Agency announced on Wednesday that it has decided to cut some subsidies for the drug, most known for its weight loss side effects. Starting this fall, the agency will only subsidize ...
Dr. Linda Niessen, KCU College of Dental Medicine: Effects of Diabetes on Oral Health
KSNF Joplin via Yahoo News· 4 days agoWhy are people with diabetes more prone to oral health issues?Diabetes is a chronic, systemic...
Health Benefits of Cardarine
Health via Yahoo News· 2 days agoA Quick Review Cardarine is a banned synthetic substance that may alter how the body metabolizes fat. Originally, the substance showed promise in...
58% Of Patients Discontinue Use Of Obesity Meds Before Reaching Meaningful Weight Loss, Study Shows
Forbes· 3 days agoThere is high demand for obesity medications known as glucagon-like peptide-1 agonists, or GLP-1s. In conjunction with an appropriate diet and exercise regimen, GLP-1s can ...
Gateway - Quartz
Quartz· 5 days agoNovo Nordisk, the maker of the mega-popular diabetes and weight loss medications Ozempic and Wegovy, is set to report its first quarter earnings on May ...
